

Supplemental content for the manuscript: The use of mathematical models of chlamydia transmission to address public health policy questions: a systematic review

References from the manuscript.

- 31s. Owusu-Edusei K, Gift TL, Chesson HW, Kent CK. Investigating the potential public health benefit of jail-based screening and treatment programs for chlamydia. *Am J Epidemiol*. 2013 Mar 1;177(5):463–73.
- 32s. Xiridou M, Vriend HJ, Lugner AK, Wallinga J, Fennema JS, Prins JM, et al. Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men. *BMC Infect Dis. BMC Infectious Diseases*; 2013 Sep 18;13(1):436.
- 33s. Vriend HJ, Lugner AK, Xiridou M, Schim van der Loeff MF, Prins M, de Vries HJC, et al. Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective. *AIDS*. 2013 Sep 10;27(14):2281–90.
- 34s. Regan DG, Wilson DP, Hocking JS. Modeling the impact of treatment failure on Chlamydia transmission and screening. *Sex Transm Dis*. 2013 Sep;40(9):700–3.
- 35s. Herzog SA, Heijne JCM, Scott P, Althaus CL, Low N. Direct and indirect effects of screening for Chlamydia trachomatis on the prevention of pelvic inflammatory disease: a mathematical modeling study. *Epidemiology*. 2013 Nov;24(6):854–62.
- 36s. Looker KJ, Wallace LA, Turner KM. Impact and cost-effectiveness of chlamydia testing in Scotland: a mathematical modelling study. *Theor Biol Med Model*. 2015 Jan 15;12(1):2.
- 37s. Teng Y, Kong N, Tu W. Optimizing strategies for population-based chlamydia infection screening among young women: an age-structured system dynamics approach. *BMC Public Health*. *BMC Public Health*; 2015 Jan;15(1):639.
- 38s. Heijne JCM, Althaus CL, Herzog SA, Kretzschmar M, Low N. The role of reinfection and partner notification in the efficacy of chlamydia screening programs. *J Infect Dis*. 2011 Feb 1;203(3):372–7.
- 39s. Althaus CL, Heijne JCM, Herzog SA, Roellin A, Low N. Individual and population level effects of partner notification for Chlamydia trachomatis. *PLoS One*. 2012 Jan;7(12):e51438.
- 40s. Owusu-Edusei K, Chesson HW, Gift TL, Brunham RC, Bolan G. Cost-effectiveness of Chlamydia Vaccination Programs for Young Women. *Emerg Infect Dis*. 2015 Jun;21(6):960–8.
- 41s. Vickerman PT, Ndowa F, O'Farrell N, Steen R, Alary M, Delany-Moretlwe S. Using mathematical modelling to estimate the impact of periodic presumptive treatment on the transmission of STIs and HIV amongst female sex workers. *Sex Transm Infect*. 2009/10/27. 2009;
- 42s. Johnson LF, Dorrington RE, Bradshaw D, Coetzee DJ. The effect of syndromic management interventions on the prevalence of sexually transmitted infections in South Africa. *Sex Reprod Healthc*. Elsevier B.V.; 2011;2(1):13–20.
- 43s. Johnson LF, Dorrington RE, Bradshaw D. The role of immunity in the epidemiology of gonorrhoea, chlamydial infection and trichomoniasis: insights from a mathematical model. *Epidemiol Infect*. Cambridge University Press; 2011 Dec 1;139(12):1875–83.
- 44s. Clarke J, White KAJ, Turner K. Approximating optimal controls for networks when there are combinations of population-level and targeted measures available: chlamydia infection as a case-study. *Bull Math Biol*. 2013 Oct;75(10):1747–77.

- 45s. Heijne JCM, Herzog SA, Althaus CL, Tao G, Kent CK, Low N. Insights into the timing of repeated testing after treatment for Chlamydia trachomatis: data and modelling study. *Sex Transm Infect.* 2012 Feb 1;89(1):1–10.
- 46s. Tuite A, Fisman D. Agent-based modelling of Chlamydia trachomatis transmission in a Canadian subpopulation. Winnipeg, Manitoba: National Collaboration Centre for Infectious Diseases; 2014.
- 47s. Althaus CL, Turner KME, Mercer CH, Auguste P, Roberts TE, Bell G, et al. Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling. *Health Technol Assess.* 2014 Jan;18(2):1–100, vii–viii.
- 48s. Gray RT, Beagley KW, Timms P, Wilson DP. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. *J Infect Dis.* 2009 Jun 1;199(11):1680–8.
- 49s. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhoea and Chlamydia using stochastic network simulations. *Am J Epidemiol.* 1996 Aug 1;144(3):306–17.
- 50s. Kretzschmar M, Welte R, van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. *Am J Epidemiol.* 2001 Jan 1;153(1):90–101.
- 51s. Welte R, Kretzschmar M, Leidl R, van den Hoek A, Jager JC, Postma MJ. Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach. *Sex Transm Dis.* 2000 Oct;27(9):518–29.
- 52s. Welte R, Postma M, Leidl R, Kretzschmar M. Costs and effects of chlamydial screening: dynamic versus static modeling. *Sex Transm Dis.* 2005 Aug;32(8):474–83.
- 53s. Andersen B, Gundgaard J, Kretzschmar M, Olsen J, Welte R, Ostergaard L, et al. Prediction of Costs, Effectiveness, and Disease Control of a Population-Based Program Using Home Sampling for Diagnosis of Urogenital Chlamydia trachomatis Infections. *Sex Transm Dis.* 2006 Jul;33(7):407–15.
- 54s. Kretzschmar M, Satterwhite C, Leichter J, Berman S. Effects of screening and partner notification on Chlamydia positivity in the United States: a modeling study. *Sex Transm Dis.* 2012 May;39(5):325–31.
- 55s. Turner KME, Adams EJ, Lamontagne DS, Emmett L, Baster K, Edmunds WJ. Modelling the effectiveness of chlamydia screening in England. *Sex Transm Infect.* 2006 Dec;82(6):496–502.
- 56s. Turner KME, Adams EJ, Gay N, Ghani AC, Mercer C, Edmunds WJ. Developing a realistic sexual network model of chlamydia transmission in Britain. *Theor Biol Med Model.* 2006 Jan;3(1):3.
- 57s. Adams EJ, Turner KME, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. *Sex Transm Infect.* 2007 Jul;83(4):267-274-275.
- 58s. Gillespie P, O'Neill C, Adams E, Turner K, O'Donovan D, Brugha R, et al. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland. *Sex Transm Infect.* 2012 Apr 1;88(3):222–8.
- 59s. Low N, McCarthy A, Macleod J, Salisbury C, Campbell R, Roberts TE, et al. Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. *Health Technol Assess.* England: Department of Preventive Medicine, University of Bristol, UK.; 2007 Mar;11(8):iii–iv, ix–xii, 1-165.
- 60s. Roberts TE, Robinson S, Barton PM, Bryan S, McCarthy A, Macleod J, et al. Cost

effectiveness of home based population screening for Chlamydia trachomatis in the UK: economic evaluation of chlamydia screening studies (ClaSS) project. *BMJ*. 2007 Aug 11;335(7614):291.

- 61s. Schmid B V., Over EAB, van den Broek IVF, Op de Coul ELM, van Bergen JEAM, Fennema JSA, et al. Effects of Population Based Screening for Chlamydia Infections in The Netherlands Limited by Declining Participation Rates. *PLoS One*. 2013 Jan;8(3):e58674.
- 62s. de Wit GA, Over E a. B, Schmid B V., van Bergen JE a. M, van den Broek IVF, van der Sande MAB, et al. Chlamydia screening is not cost-effective at low participation rates: evidence from a repeated register-based implementation study in the Netherlands. *Sex Transm Infect*. 2015 Mar 10;91(6):1–7.
- 63s. Armbruster B, Brandeau ML. Contact tracing to control infectious disease: when enough is enough. *Health Care Manag Sci*. 2007 Dec;10(4):341–55.
- 64s. Schmid B V, Kretzschmar M. Determinants of sexual network structure and their impact on cumulative network measures. *PLoS Comput Biol*. 2012 Jan;8(4):e1002470.
- 65s. Kretzschmar M, Turner KME, Barton PM, Edmunds WJ, Low N. Predicting the population impact of chlamydia screening programmes: comparative mathematical modelling study. *Sex Transm Infect*. 2009/05/21. 2009 Sep;85(5):359–66.
- 66s. Althaus CL, Turner KME, Schmid B V, Heijne JCM, Kretzschmar M, Low N. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. *J R Soc Interface*. 2011 Jun 7;9(66):136–46.
- 67s. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of Pelvic Inflammatory Disease by Screening for Cervical Chlamydial Infection. *N Engl J Med*. Massachusetts Medical Society; 1996;334:1362–6.
- 68s. Ostergaard L, Andersen B, Møller JK, Olesen F. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster-randomized 1-year follow-up study. *Clin Infect Dis*. 2000 Oct;31(January):951–7.
- 69s. Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. *Bmj*. 2010/04/10. 2010;340:c1642.
- 70s. Andersen B, van Valkengoed I, Sokolowski I, Møller JK, Østergaard L, Olesen F. Impact of intensified testing for urogenital Chlamydia trachomatis infections: a randomised study with 9-year follow-up. *Sex Transm Infect*. 2011 Mar;87(2):156–61.
- 71s. Cohen DA, Nsuami M, Martin DH, Farley TA. Repeated school-based screening for sexually transmitted diseases: a feasible strategy for reaching adolescents. *Pediatrics*. 1999 Dec;104(6):1281–5.
- 72s. Hodgins S, Peeling RW, Dery S, Bernier F, LaBrecque A, Proulx JF, et al. The value of mass screening for chlamydia control in high prevalence communities. *Sex Transm Infect*. 2002 Apr;78 Suppl 1:i64-8.
- 73s. van den Broek IVF, van Bergen JE a. M, Brouwers EEHG, Fennema JS a., Gotz HM, Hoebe CJP, et al. Effectiveness of yearly, register based screening for chlamydia in the Netherlands: controlled trial with randomised stepped wedge implementation. *Bmj*. 2012 Jul 5;345(July):e4316–e4316.
- 74s. García PJ, Holmes KK, Cárcamo CP, Garnett GP, Hughes JP, Campos PE, et al. Prevention of sexually transmitted infections in urban communities (Peru PREVEN): A multicomponent community-randomised controlled trial. *Lancet*. 2012;379(9821):1120–8.

- 75s. Schillinger JA, Kissinger P, Calvet H, Whittington WLH, Ransom RL, Sternberg MR, et al. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women: a randomized, controlled trial. *Sex Transm Dis.* 2003 Jan;30(1):49–56.
- 76s. Golden MR, Whittington WLH, Handsfield HH, Hughes JP, Stamm WE, Hogben M, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. *N Engl J Med.* 2005;352(7):676–85.
- 77s. Kissinger P, Mohammed H, Richardson-Alston G, Leichter JS, Taylor SN, Martin DH, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. *Clin Infect Dis.* 2005;41(5):623–9.
- 78s. Cameron ST, Glasier A, Scott G, Young H, Melvin L, Johnstone A, et al. Novel interventions to reduce re-infection in women with chlamydia: A randomized controlled trial. *Hum Reprod.* 2009;24(4):888–95.
- 79s. Giertz G, Kallings I, Nordenvall M, Fuchs T. A prospective study of Chlamydia trachomatis infection following legal abortion. *Acta Obstet Gynecol Scand.* 1987;66(2):107–9.
- 80s. Penney GC, Thomson M, Norman J, McKenzie H, Vale L, Smith R, et al. A randomised comparison of strategies for reducing infective complications of induced abortion. *Br J Obstet Gynaecol.* 1998;105(June):599–604.
- 81s. Price MJ, Ades AE, de Angelis D, Welton NJ, Macleod J, Turner K, et al. Incidence of Chlamydia trachomatis infection in women in England: two methods of estimation. *Epidemiol Infect.* 2014 Mar;142(3):562–76.
- 82s. Price MJ, Ades A, Welton NJ, Macleod J, Turner K, Simms I, et al. How much tubal factor infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity. *Sex Transm Dis.* 2012 Aug;39(8):608–13.
- 83s. Price MJ, Ades a. E, De Angelis D, Welton NJ, MacLeod J, Soldan K, et al. Risk of pelvic inflammatory disease following chlamydia trachomatis infection: Analysis of prospective studies with a multistate model. *Am J Epidemiol.* 2013 Jun 27;178(3):484–92.
- 84s. Davies B, Ward H, Leung S, Turner KME, Garnett GP, Blanchard JF, et al. Heterogeneity in risk of pelvic inflammatory diseases after chlamydia infection: a population-based study in Manitoba, Canada. *J Infect Dis.* 2014 Dec 1;210 Suppl(suppl_2):S549-55.
- 85s. Davies B, Turner KME, Frølund M, Ward H, May MT, Rasmussen S, et al. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. *Lancet Infect Dis.* Elsevier; 2016 Sep;16(9):1057–64.
- 86s. Heijne JCMM, Herzog SA, Althaus CL, Low N, Kretzschmar M. Case and partnership reproduction numbers for a curable sexually transmitted infection. *J Theor Biol.* Elsevier; 2013 Aug 21;331:38–47.